This finding indicates that erythropoiesis in PV is still sensitive to the stimulating activity of macrophages and identifies these macrophages as a potential therapeutic target to counteract the exaggerated erythropoiesis induced by the JAK2(V617F) mutation. This evidence concerns the gene JAK2 and acquired polycythemia vera.